SCHEMBL10150608

SCHEMBL10150608

C=CC(=O)OCCSCCC

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 8/20 0.60
HPGD P15428 1/20 0.60
ALDH1A1 P00352 5/20 0.50
TP53 P04637 3/20 0.50
HIF1A Q16665 3/20 0.50
CYP3A4 P08684 2/20 0.50
HSD17B10 Q99714 1/20 0.50
THRB P10828 4/20 0.46
ATM Q13315 1/20 0.39
HCAR2 Q8TDS4 4/20 0.37
MAPK1 P28482 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
TDP1 Q9NUW8 1/20 0.34
MAPT P10636 1/20 0.31
RAB9A P51151 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL672392 0.90 TSHR (0.60) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL10033081 0.89 TSHR (0.67) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL672840 0.88 TSHR (0.58) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL7563889 0.88 TSHR (0.58) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL673220 0.88 TSHR (0.58) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL21385195 0.87 TSHR (0.53) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL4888473 0.86 TSHR (0.57) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL6408701 0.86 TSHR (0.62) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL22710146 0.86 TSHR (0.62) TSHRHPGDALDH1A1TP53HIF1A
SCHEMBL6086010 0.86 TSHR (0.62) TSHRHPGDALDH1A1TP53HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8329377-B2 Imide compound and chemically amplified resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-12-11 US disclosed
US-8173350-B2 Oxime compound and resist composition containing the same SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-05-08 US disclosed
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-02-04 US disclosed
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2010-01-28 US disclosed
US-7638575-B2 Imparts excellent water repellency, oil repellency and soil resistance to a textile, a masonry, a filter (for example, an electrostatic filter), a dust protective mask, and a part of fuel cell; acrylic ester or amide polymer DAIKIN INDUSTRIES, LTD. (JP) 2009-12-29 US disclosed
US-20090256102-A1 FLUOROPOLYMER AND SOIL REMOVER DAIKIN INDUSTRIES, LTD. (JP) 2009-10-15 US disclosed
US-20070173148-A1 Surface treating agent, fluorine-containing monomer and fluorine-containing polymer DAIKIN INDUSTRIES LTD. (JP) 2007-07-26 US disclosed
US-7223516-B2 Positive type photoresist composition FUJIFILM CORPORATION (JP) 2007-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070173148-A1 Surface treating agent, fluorine-containing monomer and fluorine-containing polymer PYM1, AFF1, AFF2 TSHR 506/4885HPGD 4261/4885ALDH1A1 3476/4885
US-20100028807-A1 Imide Compound and Chemically Amplified Resist Composition Containing The Same IGF1R, CCNA1, MYC TSHR 2519/4885HPGD 4030/4885ALDH1A1 386/4885
US-20100021847-A1 Oxime Compound and Resist Composition Containing the Same CYC1, UQCRB, CBR1 TSHR 841/4885HPGD 1910/4885ALDH1A1 1280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.